CoChat

Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Impaired estrogens action is associated with features of the metabolic syndrome in animal models and humans. We sought to determine whether disruption of hepatic estrogens action in adult male mice could recapitulate aspects of the metabolic syndrome to understand the mechanistic basis for the phenotype. We found 17β-estradiol (E 2) inhibited hepatic gluconeogenic genes such as phosphoenolpyruvate carboxykinase 1 (Pck-1) and glucose 6-phosphatase (G6Pase) and this effect was absent in mice lacking l iver e strogen r eceptor α (Esr1) (LERKO mice). Male LERKO mice displayed elevated hepatic gluconeogenic activity and fasting hyperglycemia. We also observed increased liver lipid deposits and triglyceride levels in male LERKO mice, resulting from increased hepatic lipogenesis as reflected by increased mRNA levels of fatty acid synthase (Fas) and acetyl-CoA carboxylase (Acc1). ChIP assay demonstrated estradiol (E 2) induced ESR1 binding to Pck-1, G6Pase, Fas and Acc1 promoters. Metabolic phenotyping demonstrated both basal metabolic rate and feeding were lower for the LERKO mice as compared to Controls. Furthermore, the respiratory exchange rate was significantly lower in LERKO mice than in Controls, suggesting an increase in lipid oxidation. Our data indicate that hepatic E 2/ESR1 signaling plays a key role in the maintenance of gluconeogenesis and lipid metabolism in males.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-01937-4

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Knock down of hepatic ESR1 in the LERKO mice. (A–D) mRNA levels of ESR1 in liver, muscle, fat and hypothalamus measured by q-RT-PCR. (E–L) immunofluorescence staining of hepatic ESR1 from Control (E–H) and LERKO mice liver (I–L). (E,I) ESR1 staining. (F,J) GFP fluorescence. (G,K) DAPI staining. (H,L) merged images. (M) ImageJ quantification of immunofluorescence staining (n = 6). Data are expressed as the means ± SD, *p < 0.05 versus Control, **p < 0.01 versus Control, ***p < 0.001 versus Control.
Figure 1 Knock down of hepatic ESR1 in the LERKO mice. (A–D) mRNA levels of ESR1 in liver, muscle, fat and hypothalamus measured by q-RT-PCR. (E–L) immunofluorescence staining of hepatic ESR1 from Control (E–H) and LERKO mice liver (I–L). (E,I) ESR1 staining. (F,J) GFP fluorescence. (G,K) DAPI staining. (H,L) merged images. (M) ImageJ quantification of immunofluorescence staining (n = 6). Data are expressed as the means ± SD, *p < 0.05 versus Control, **p < 0.01 versus Control, ***p < 0.001 versus Control.CC BY · PubMed Central
Figure 2 Glucose, insulin and pyruvate tolerance tests. (A) Glucose tolerance test (GTT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Glucose (2 g/kg body weight) was administrated by intraperitoneal injection after overnight fasting. (D) Area under the curve of the GTT displayed in (A). (B) Insulin tolerance test (ITT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Insulin (0.3 U/kg body weight) was administrated by intraperitoneal injection after 7 hours fasting. (E) Area under the curve of the ITT displayed in (B). (C) Pyruvate challenge test (PCT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Pyruvate (2 g/kg body weight) was administrated by intraperitoneal injection after 6 hours fasting. (F) Area under the curve of the PCT displayed in (C). *p < 0.05 versus Control. (G–H) 6 hours and 16 hours fasting glucose of Control and LERKO mice. *p < 0.05, ***p < 0.001 versus Control (Fig. 2A–H). (I) Glucose production assays were conducted in primary hepatocytes from Control and LERKO mice; cells were subjected to 4 hours of serum starvation before the addition of E2 for 12 hours. The experiments were performed 1–3 weeks after virus injection. The data are expressed as the means ± SD, *p < 0.05, vehicle versus E2 treatment, ## p < 0.01 Control versus LERKO (Fig. 2I).
Figure 2 Glucose, insulin and pyruvate tolerance tests. (A) Glucose tolerance test (GTT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Glucose (2 g/kg body weight) was administrated by intraperitoneal injection after overnight fasting. (D) Area under the curve of the GTT displayed in (A). (B) Insulin tolerance test (ITT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Insulin (0.3 U/kg body weight) was administrated by intraperitoneal injection after 7 hours fasting. (E) Area under the curve of the ITT displayed in (B). (C) Pyruvate challenge test (PCT) was performed on Control (circle symbols) and LERKO (square symbols) mice. Pyruvate (2 g/kg body weight) was administrated by intraperitoneal injection after 6 hours fasting. (F) Area under the curve of the PCT displayed in (C). *p < 0.05 versus Control. (G–H) 6 hours and 16 hours fasting glucose of Control and LERKO mice. *p < 0.05, ***p < 0.001 versus Control (Fig. 2A–H). (I) Glucose production assays were conducted in primary hepatocytes from Control and LERKO mice; cells were subjected to 4 hours of serum starvation before the addition of E2 for 12 hours. The experiments were performed 1–3 weeks after virus injection. The data are expressed as the means ± SD, *p < 0.05, vehicle versus E2 treatment, ## p < 0.01 Control versus LERKO (Fig. 2I).CC BY · PubMed Central
Figure 3 ESR1 inhibition of gluconeogenic gene expression is E2 dependent. (A,B) Hepatic mRNA levels of G6Pase and Pck1 from Control mice and LERKO mice (n >= 6 per genotype). (C,D) Primary hepatocytes from Control mice were treated with vehicle or different doses of E2 (10−12 M, 10−11 M, 10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR. F-H, primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR. (E,F) Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR.G-H, ChIP assay experiments were performed with liver tissues using antibody to ESR1, or with rabbit preimmune serum (IgG) and primers flanking the G6Pase (G) and Pck1 (H) promoters. Real-time PCR data with an inset of a 1.5% agarose gel as a representative example. Results were normalized to input and shown as fold enrichment IgG from 3 independent ChIP experiments. The experiments were performed 2 weeks after virus injection. The data are expressed as the means ± SD, *p < 0.05 versus control, *p < 0.05 versus vehicle, ### p < 0.001 versus control.
Figure 3 ESR1 inhibition of gluconeogenic gene expression is E2 dependent. (A,B) Hepatic mRNA levels of G6Pase and Pck1 from Control mice and LERKO mice (n >= 6 per genotype). (C,D) Primary hepatocytes from Control mice were treated with vehicle or different doses of E2 (10−12 M, 10−11 M, 10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR. F-H, primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR. (E,F) Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M), mRNA levels of G6Pase and Pck1 were measured by q-RT-PCR.G-H, ChIP assay experiments were performed with liver tissues using antibody to ESR1, or with rabbit preimmune serum (IgG) and primers flanking the G6Pase (G) and Pck1 (H) promoters. Real-time PCR data with an inset of a 1.5% agarose gel as a representative example. Results were normalized to input and shown as fold enrichment IgG from 3 independent ChIP experiments. The experiments were performed 2 weeks after virus injection. The data are expressed as the means ± SD, *p < 0.05 versus control, *p < 0.05 versus vehicle, ### p < 0.001 versus control.CC BY · PubMed Central
Figure 4 E2/ESR1 signaling inhibits hepatic lipogenesis. Representative images of liver sections from Control (A) and LERKO (B) mice after staining with Oil Red O as a measure of lipid accumulation (magnification: ×20). n = 3 per group. (C) Quantification of Oil Red O staining using Image (J). (D) Hepatic triglyceride levels in Control and LERKO mice. (E,F) mRNA levels of hepatic lipogenic genes Fas and Acc1 in Control and LERKO mice were measured by q-RT-PCR. (C–F) *p < 0.05 versus Control, **p < 0.01 versus Control. Data from Fig. 4E,F are representative of results obtained from 6–10 mice in each group. (G,H). Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M) or GPER agonist G-1 (10−10 M, 10−9 M, 10−8 M), mRNA levels of Fas and Acc1 were measured by q-RT-PCR. *p < 0.05 versus vehicle, **p < 0.01 versus vehicle, ***p < 0.001 versus vehicle. (I,J) Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M) in absence or in presence of GPER antagonist G-15 (10−8 M), mRNA levels of Fas and Acc1 were measured by q-RT-PCR. *p < 0.05 versus vehicle, **p < 0.01 versus vehicle, ***p < 0.001 versus vehicle. (K,L) ChIP assay experiments were performed with liver tissues using antibody to ESR1, or with rabbit preimmune serum (IgG) and primers flanking the Fas (K) and Acc1 (L) promoters. Real-time PCR data with an inset of a 1.5% agarose gel as a representative example. Results were normalized to input and shown as fold enrichment IgG from 3 independent ChIP experiments. The experiments were performed 2 weeks after virus injection. Values are means ± SD. *p < 0.05 versus IgG, ***p < 0.001 versus IgG.
Figure 4 E2/ESR1 signaling inhibits hepatic lipogenesis. Representative images of liver sections from Control (A) and LERKO (B) mice after staining with Oil Red O as a measure of lipid accumulation (magnification: ×20). n = 3 per group. (C) Quantification of Oil Red O staining using Image (J). (D) Hepatic triglyceride levels in Control and LERKO mice. (E,F) mRNA levels of hepatic lipogenic genes Fas and Acc1 in Control and LERKO mice were measured by q-RT-PCR. (C–F) *p < 0.05 versus Control, **p < 0.01 versus Control. Data from Fig. 4E,F are representative of results obtained from 6–10 mice in each group. (G,H). Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M) or GPER agonist G-1 (10−10 M, 10−9 M, 10−8 M), mRNA levels of Fas and Acc1 were measured by q-RT-PCR. *p < 0.05 versus vehicle, **p < 0.01 versus vehicle, ***p < 0.001 versus vehicle. (I,J) Primary hepatocytes from Control and LERKO mice were treated with vehicle or different doses of E2 (10−10 M, 10−9 M, 10−8 M) in absence or in presence of GPER antagonist G-15 (10−8 M), mRNA levels of Fas and Acc1 were measured by q-RT-PCR. *p < 0.05 versus vehicle, **p < 0.01 versus vehicle, ***p < 0.001 versus vehicle. (K,L) ChIP assay experiments were performed with liver tissues using antibody to ESR1, or with rabbit preimmune serum (IgG) and primers flanking the Fas (K) and Acc1 (L) promoters. Real-time PCR data with an inset of a 1.5% agarose gel as a representative example. Results were normalized to input and shown as fold enrichment IgG from 3 independent ChIP experiments. The experiments were performed 2 weeks after virus injection. Values are means ± SD. *p < 0.05 versus IgG, ***p < 0.001 versus IgG.CC BY · PubMed Central
Figure 5 Reduced energy expenditure in LERKO mice. (A) Real-time monitoring curve of carbon dioxide release (VCO2). (B) Quantification of carbon dioxide release. (C) Real-time monitoring curve of oxygen consumption (VO2). (D) Quantification of O2 consumption. (E) Real-time monitoring curve of accumulated food intake. (F) Quantification of food intake. G, Respiratory exchange ratio (RER = VCO2/VO2) (H), Calculated body heat. (I) Locomotor activity. (J) Body weight measurement of Control group and LERKO group on GFP or CRE virus injection day 0, 4, 8, 12, 16. The experiments were performed 3 weeks after virus injection. Values are means ± SD. *p < 0.05.
Figure 5 Reduced energy expenditure in LERKO mice. (A) Real-time monitoring curve of carbon dioxide release (VCO2). (B) Quantification of carbon dioxide release. (C) Real-time monitoring curve of oxygen consumption (VO2). (D) Quantification of O2 consumption. (E) Real-time monitoring curve of accumulated food intake. (F) Quantification of food intake. G, Respiratory exchange ratio (RER = VCO2/VO2) (H), Calculated body heat. (I) Locomotor activity. (J) Body weight measurement of Control group and LERKO group on GFP or CRE virus injection day 0, 4, 8, 12, 16. The experiments were performed 3 weeks after virus injection. Values are means ± SD. *p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 135

Metadata

Authors
Qiu, S., Vazquez, J. T., Boulger, E., Liu, H., Xue, P., Hussain, M. A., & Wolfe, A.
Affiliations
  • Johns Hopkins University (US)
  • Ponce Health Sciences University (PR)
Corresponding author
Wolfe, Andrew
Venue
Scientific Reports
Published
2017-05-10
Volume
7
Issue
1
Pages
1661-1661
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2610476257
Cited by
135
References
55
Citations by year
2026: 11 · 2025: 15 · 2024: 18 · 2023: 16 · 2022: 14 · 2021: 15 · 2020: 21 · 2019: 14 · 2018: 7 · 2017: 4
FWCI
8.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Wisconsin-Madison
  • Johns Hopkins University
  • National Institutes of Health (DK-079637)
  • Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007751, P30DK079637, R01DK101591)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD068777)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
ESR1, estradiol, gluconeogenesis, hepatic lipid metabolism, metabolic syndrome, PCK1, glucose-6-phosphatase, fatty acid synthase, acetyl-CoA carboxylase 1, hepatic lipogenesis, fasting hyperglycemia, liver fat deposition, transcriptional regulation, male mice
MeSH terms
Animals, Body Weight, Energy Metabolism, Estradiol, Gene Expression Regulation, Gluconeogenesis, Glucose, Insulin, Liver, Male, Organ Specificity, Signal Transduction, Mice, Knockout, Pyruvic Acid, Estrogen Receptor alpha, Lipid Metabolism, Gene Knockdown Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males. https://app.cochat.ai/papers/10.1038/s41598-017-01937-4
The paper
Qiu, S., Vazquez, J. T., Boulger, E., Liu, H., Xue, P., Hussain, M. A., & Wolfe, A. (2017). Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males. Scientific Reports. https://doi.org/10.1038/s41598-017-01937-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.